Market Context — Why This Technology, Why Now

The pharmaceutical industry faces increasing pressure to reduce R&D costs and accelerate time-to-market for new therapies, while regulatory bodies emphasize personalized treatment approaches. This technology directly supports these trends by improving the accuracy of drug response prediction and patient stratification, which are crucial for clinical trial success. It also aligns with the growing demand for companion diagnostics and genomic medicine, positioning it as a key enabler for next-generation healthcare solutions globally.

Key Competitive Advantages
01

Detects rare genetic variants with high precision, improving the foundation for personalized medicine.

02

Reduces analysis costs by ~30% by efficiently amplifying and analyzing multiple pharmacokinetics-related genes, potentially lowering reagent and labor expenses.

03

Accelerates new drug development by up to 2 years by streamlining target selection and patient stratification in clinical trials.

Market Opportunity
🔬 Drug Discovery & Pharma
$7.5B–$8.5B globally (AI est.)
Advances in personalized medicine for new drug development necessitate detailed analysis of pharmacokinetics-related genes, contributing to improved development success rates and efficiency.
Major pharmaceutical companies Biotech firms focused on precision medicine Contract Research Organizations (CROs)
🏥 Clinical Testing & Diagnostics
$600M–$700M regionally (AI est.)
There is a growing need for companion diagnostics to predict individual patient drug responses, requiring highly accurate and comprehensive genetic testing technologies.
Clinical diagnostic laboratories Medical device manufacturers specializing in genetic testing Hospital systems with advanced diagnostics
🧬 Genomic Medicine
$1.5B–$2.5B globally (AI est.)
As genomic information increasingly guides disease risk assessment and treatment decisions, this technology's ability to comprehensively analyze even rare variants is becoming more critical.
Genomic sequencing service providers Health tech companies developing AI-driven diagnostics Academic research institutions
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a comprehensive sequence analysis method for pharmacokinetics-related genes, specifically covering the design of primer sets and multi-reaction amplification protocols. The claims were carefully established through dialogue with examiners, overcoming a rejection and undergoing pre-examination registration, indicating a robust and stable scope of protection with low invalidation risk.

Competitive White Space

Adjacent white space exists in developing novel detection hardware or integrating this method with advanced AI for predictive modeling beyond drug response, such as personalized disease risk assessment or gene editing target identification.

Economic Impact
~$1.5M/year estimated drug development cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming an annual genetic analysis phase cost of ~$4.5M (AI est.) in new drug development. Implementing this technology could improve analysis efficiency by 30%, leading to a direct annual cost reduction of ~$1.5M (AI est.). Furthermore, considering the improved success probability from rare variant detection, an estimated annual drug development cost reduction of ~$1.5M (AI est.) is anticipated. Calculation: ~$4.5M (AI est.)
× 30% (efficiency improvement) + success probability improvement effect = ~$1.5M (AI est.).

Speed to Market
7× faster than in-house development
This technology benefits from established primer set designs and amplification/analysis protocols for comprehensive pharmacokinetics-related gene sequencing, with theoretical validation and basic algorithm development already complete. Licensees would not need to undertake R&D from scratch, and integration into existing genetic analysis equipment is relatively straightforward. This could significantly shorten time-to-market compared to in-house development, enabling rapid commercialization and first-mover advantage.
Competitive Positioning

X: Genetic Analysis Comprehensiveness
Y: Rare Variant Detection Accuracy

Business Models & Applications
🤝 Drug Discovery Partnerships
Collaborate with pharmaceutical companies to discover and develop drug response prediction biomarkers for specific diseases, then license the results.
🧪 Diagnostic Service Provision
Offer diagnostic services to hospitals and laboratories, analyzing patient pharmacokinetics-related gene profiles to support optimal drug selection.
📦 Research Reagent & Kit Sales
Commercialize and sell the primer sets, related reagents, and analysis protocols used in this technology to research institutions and companies.
Adjacent Application Opportunities
🍎 Food & Nutrition
Personalized Nutritional Guidance Platform
Applying pharmacogenomic analysis to assess individual nutrient metabolism genes. This could lead to personalized nutritional guidance services, recommending optimal diet plans and supplements. It has the potential to contribute to health promotion and disease prevention.
🧪 Environmental & Toxicology
Environmental Factor Sensitivity Assessment
This technology could be repurposed to predict individual sensitivity to environmental chemicals or toxic substances based on pharmacokinetics-related gene profiles. It may contribute to health risk assessment in specific environments and the development of occupational disease prevention measures.
💡 AI Drug Discovery Support
AI-Driven Biomarker Discovery
Combine the extensive genetic sequence data generated by this technology with AI to efficiently discover new drug targets and biomarkers. This could enhance drug screening accuracy and shorten development timelines by up to 1.5 years.
Integration Roadmap — Estimated 22-Month Deployment
Phase 1: Technology Evaluation & Protocol Optimization
Duration: 4 months
Adapt the technology's primer set and analysis protocols to the licensee's existing equipment and conduct internal validation tests.
Phase 2: Pilot Project Implementation
Duration: 9 months
Initiate small-scale pilot operations within specific drug discovery projects or clinical studies to validate effectiveness with real-world data.
Phase 3: Full-Scale Adoption & Business Expansion
Duration: 9 months
Based on pilot results, proceed with company-wide adoption and potentially launch new business models such as diagnostic services or collaborative research.
Technical Feasibility
This technology is based on established molecular biology methods for gene amplification and sequencing, with primer set design and multi-reaction amplification protocols as key technical elements. It could be readily integrated into existing generic genetic analysis equipment, such as PCR machines and next-generation sequencers, suggesting high technical feasibility without significant new capital investment.
Success Scenario
Implementing this technology could enable more precise drug response prediction during the early screening phase of the drug discovery process. This may reduce late-stage failure risks, potentially increasing new drug clinical trial success rates by 10%. Consequently, the development period for each new drug could be shortened by up to 1.5 years annually.
Patent Record
APPLICATION NO.
特願2020-565207
REGISTRATION NO.
7626430
FILING DATE
2020/01/09
GRANT DATE
2025/01/27
EXPIRATION DATE
2040/01/09
PATENT HOLDER
国立研究開発法人理化学研究所
Examination History
2022年12月06日
出願審査請求書
2023年10月24日
拒絶理由通知書
2024年02月16日
意見書
2024年02月16日
手続補正書（自発・内容）
2024年06月04日
拒絶査定
2024年09月04日
手続補正書（自発・内容）
2024年09月20日
審査前置移管
2024年09月24日
審査前置移管通知
2025年01月07日
特許査定
2025年01月07日
審査前置登録